title: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study.
abstract: Purpose Primary peritoneal serous carcinoma (PPSC) is a rare condition with a poor survival rate, even after treatment with debulking surgery followed by systemic chemotherapy. This study evaluated the efficacy and safety of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of PPSC. Patients and methods This retrospective study included 22 female patients with primary advanced PPSC (group A, n = 12) or recurrent PPSC (group B, n = 10) treated with 25 CRS + HIPEC procedures. The primary end point was overall survival (OS), and the secondary end points were safety profiles. Results A total of 25 CRS + HIPEC procedures were performed in these 22 patients. The median OS was 31.0 months (95% confidence interval (CI) 22.3-39.7), and the 1-, 3-, and 5-year survival rates were 100%, 45.5%, and 27.3%, respectively. Subgroup analyses revealed that the median OS was 31.0 months (95% CI 19.8-42.2) for group A vs. 38.5 months (95% CI 9.6-67.4) for group B (P = 0.832, log rank test); 51.5 months (95% CI 34.9-68.1) for peritoneal cancer index (PCI) ≤ 15 vs. 20.3 months (95% CI 12.6-28.0) for PCI > 15 (P = 0.000, log rank test); and 38.5 months (95% CI 22.5-54.5) for completeness of cytoreduction (CC) of 0-1 vs. 23.5 months (95% CI 15.3-31.7) for CC of 2-3 (P = 0.178, log rank test). There were no perioperative deaths. Serious adverse events (SAEs) occurred in two patients (9.1%). A univariate analysis identified PCI ≤ 15 as the only prognostic predicator (hazard ratio (HR) 13.1, 95% CI 2.7-63.4, P = 0.001). Conclusions CRS + HIPEC could contribute to favourable outcomes for select PPSC patients with acceptable safety profiles.
authors.affiliation: a Department of Oncology , Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumour Biological Behaviours and Hubei Cancer Clinical Study Centre , Wuhan , China ;|b Department of Gastrointestinal Surgery , Central Hospital of Enshi Tujia and Miao Autonomous Prefecture , Enshi , Hubei , China ;
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Sun
authors.affiliation: a Department of Oncology , Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumour Biological Behaviours and Hubei Cancer Clinical Study Centre , Wuhan , China ;
authors.forename: Zhong-He
authors.initials: ZH
authors.lastname: Ji
authors.affiliation: a Department of Oncology , Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumour Biological Behaviours and Hubei Cancer Clinical Study Centre , Wuhan , China ;
authors.forename: Kai-Wen
authors.initials: KW
authors.lastname: Peng
authors.affiliation: a Department of Oncology , Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumour Biological Behaviours and Hubei Cancer Clinical Study Centre , Wuhan , China ;
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Wu
authors.affiliation: a Department of Oncology , Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumour Biological Behaviours and Hubei Cancer Clinical Study Centre , Wuhan , China ;
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: c NPO Organization to Support Peritoneal Dissemination Treatment , Osaka , Japan ;
authors.forename: Yukata
authors.initials: Y
authors.lastname: Yonemura
authors.affiliation: a Department of Oncology , Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumour Biological Behaviours and Hubei Cancer Clinical Study Centre , Wuhan , China ;|d Department of Peritoneal Cancer Surgery , Beijing Shijitan Hospital Affiliated to the Capital Medical University , Beijing , China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002681:China; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures; D000077143:Docetaxel; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use; D017239:Paclitaxel / Q000627:therapeutic use; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D016685:Mitomycin; D017239:Paclitaxel; D002945:Cisplatin
keywords: Cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; primary peritoneal serous carcinoma